Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617

ABSTRACTAn 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were perf...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2016-07, Vol.41 (7), p.572-573
Main Authors: Schlenkhoff, Carl Diedrich, Knüpfer, Eberhard, Essler, Markus, Ahmadzadehfar, Hojjat
Format: Article
Language:English
Subjects:
Aged, 80 and over
Dipeptides - therapeutic use
Heterocyclic Compounds, 1-Ring - therapeutic use
Humans
Lutetium - therapeutic use
Male
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
Prostatic Neoplasms, Castration-Resistant - pathology
Prostatic Neoplasms, Castration-Resistant - radiotherapy
Radioisotopes
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTAn 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000001200